SSA Swiss Advisors AG Takes Position in Novo Nordisk A/S (NYSE:NVO)

Key Points

• SSA Swiss Advisors AG acquired a new stake in Novo Nordisk A/S, purchasing 47,056 shares valued at approximately $3.27 million, making it the company's 21st largest position.
• Institutional investors collectively own 11.54% of Novo Nordisk A/S, with significant stake increases by firms such as Bank of America Corp DE and Nuveen Asset Management LLC in the previous quarters.
• Despite earning per share meeting expectations, Novo Nordisk A/S shares have seen a 21.8% decline recently, prompting varied analyst ratings from "underperform" to "strong buy".

SSA Swiss Advisors AG acquired a new position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 47,056 shares of the company's stock, valued at approximately $3,274,000. Novo Nordisk A/S accounts for about 1.7% of SSA Swiss Advisors AG's holdings, making the stock its 21st biggest holding.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. North Star Investment Management Corp. lifted its position in shares of Novo Nordisk A/S by 18.2% during the first quarter. North Star Investment Management Corp. now owns 20,742 shares of the company's stock worth $1,440,000 after purchasing an additional 3,200 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in Novo Nordisk A/S by 6.0% in the first quarter. Bank of New York Mellon Corp now owns 839,802 shares of the company's stock worth $58,316,000 after acquiring an additional 47,804 shares during the period. Stanley Laman Group Ltd. purchased a new stake in Novo Nordisk A/S in the first quarter worth about $390,000. Dover Advisors LLC purchased a new stake in Novo Nordisk A/S in the first quarter worth about $505,000. Finally, GAMMA Investing LLC lifted its stake in Novo Nordisk A/S by 9.6% in the first quarter. GAMMA Investing LLC now owns 9,466 shares of the company's stock worth $657,000 after acquiring an additional 827 shares during the period. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Down 6.0%

Novo Nordisk A/S stock traded down $3.01 during trading hours on Thursday, reaching $47.02. The stock had a trading volume of 50,205,463 shares, compared to its average volume of 15,299,037. The company has a market cap of $209.94 billion, a price-to-earnings ratio of 13.91, a PEG ratio of 0.97 and a beta of 0.64. The company has a debt-to-equity ratio of 0.70, a current ratio of 0.74 and a quick ratio of 0.56. The business's 50 day moving average price is $69.64 and its 200-day moving average price is $72.95. Novo Nordisk A/S has a 52 week low of $46.90 and a 52 week high of $139.74.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.92. Novo Nordisk A/S had a net margin of 34.52% and a return on equity of 80.94%. The firm had revenue of $11.87 billion for the quarter. Sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on NVO. Wall Street Zen raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Saturday, June 14th. BNP Paribas began coverage on shares of Novo Nordisk A/S in a research note on Tuesday, April 15th. They issued an "underperform" rating for the company. HSBC lowered shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $57.00 price objective for the company. in a research note on Thursday. Dbs Bank lowered shares of Novo Nordisk A/S to a "sell" rating in a research note on Friday, April 25th. Finally, BMO Capital Markets reiterated a "market perform" rating and issued a $64.00 target price (down from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $93.67.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.